This website is intended for Healthcare Professionals outside of the UK and US.

Symptoms Of Scpcd Cover Desktop

What to consider when facing purpura fulminans

key learnings for the management
of purpura fulminans

This information has been assembled by Takeda from the published literature. It may reflect varying clinical practices and is not intended to be a substitute for clinical guidelines and training

Purpura fulminans results from severe protein c deficiency,
which may be acquired or inherited (congenital)1-3

Facing Purpura

For information only. Diagnosis should be based on clinical guidance and training. Treatment decisions should always be based on the label of approved medications, and clinical training and expertise.Learn more about managing SCPCD
*Distinguishing between congenital and acquired PC and PS deficiency may prove difficult in the acute setting1.
**Genetic testing of the child and family members can be useful to confirm the diagnosis, but it is not readily available in most centres and the results would not be timely to guide management of these critically ill patients.

References:

  1. Findley T, et al. Acquired Versus Congenital Neonatal Purpura Fulminans: A Case Report and Literature Review. J Pediatr Hematol Oncol. 2018;40(8):625-627

  2. Goldenberg N, Manco-Johnson M. Protein C deficiency. Haemophilia. 2008;14(6):1214-1221.

  3. Price VE, et al. Diagnosis and management of neonatal purpura fulminans. Semin Fetal Neonatal Med. 2011;16(6):318-22.

  4. Özkan G, et al. Acute Kidney Injury in case of Purpura Fulminans Developing Secondary to Antithrombin 3 Deficiency. J Nippon Med Sch. 2018;85(1):56-59.

  5. Chalmers E, et al. Purpura fulminans: recognition, diagnosis and management. Archives of Disease in Childhood. 2011;96(11):1066-1071.

  6. Khor B, et al. Laboratory tests for protein C deficiency. Am J Hematol. 2010;85:440-442

  7. Tairaku S, et al. Prenatal genetic testing for familial severe congenital protein C deficiency. Hum Genome Var. 2015;2:15017.

  8. Rhodes A, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304-377.

  9. Libourel EJ, et al. Protein C/S ratio, an accurate and simple tool to identify carriers of protein C gene mutation. Br J Haematol. 2002;118:615-618.

  10. Veldman A, et al. Human protein C concentrate in the treatment of purpura fulminans: a retrospective analysis of safety and outcome in 94 pediatric patients. Crit Care. 2010;14(4):R156.

 

C-ANPROM /INT/ /5460- November 2019

PURPURA FULMINANS INVESTIGATION Decision White (1)

Interested in severe congenital protein c
Deficiency (SCPCD) and its management ?
Sign up below !

Sorry! There are some errors below that need to be fixed.
There seems to have been an error when sending the form.

You have the right to opt out of receiving such electronic communications and/or our newsletter, at any time, by using the opt out link in the communication or by contacting us at privacyoffice@takeda.com. For more information on how Takeda processes your personal data, please refer to our Privacy Notice

Please include @ in your email adress
*Required
Register

Thanks

Thank you for submitting your details

You are about to leave this website. Takeda has no influence or control over the content of this third party website.
Continue Cancel
WELCOME TO SCPCD.ORG
This website is intended for Healthcare Professionals outside of the US and the UK. The website has been developed by Takeda in accordance with industry and legal standards. Takeda makes every reasonable effort to include accurate and current information. However, the information provided on the website is not exhaustive.
Please tick the boxes to enter the site

Yes, I am a healthcare professional outside of the US and UK

YES

No, I am not a healthcare professional outside of the US and UK

NO